Idiopathic Pulmonary Fibrosis clinical trials at UC Irvine
3 research studies open to eligible people
BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
open to eligible people ages 40 years and up
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Orange, California and other locations
Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
open to eligible people ages 40 years and up
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Orange, California and other locations
TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
open to eligible people ages 40 years and up
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Orange, California and other locations
Our lead scientists for Idiopathic Pulmonary Fibrosis research studies include Bassam Yaghmour, MD.
Last updated: